Recent modelling research shows that the development of a HIV/AIDS vaccine would be a vital component to ending the disease.
The study, which focused on low- and middle-income countries, shows that adding a vaccine could significantly reduce new HIV infections and AIDS-related fatalities. One analysis example shows that with good uptake, a 70% effective vaccine could reduce new infections by 44% in the first 10 years, and by 65% in 25 years.
The data illustrate how a vaccine could significantly reduce treatment costs and potentially total HIV/AIDS response costs over time. A wide range of product characteristics would contribute to this improvement – higher efficacy, longer-lasting protection, fewer doses, lower vaccine costs and a more effective rollout.
“These new analyses underscore the powerful potential of an AIDS vaccine to help save and improve the lives of millions in a cost-effective manner,” said Mark Feinberg, President and CEO of the International AIDS Vaccine Initiative (IAVI), which conducted the study in partnership with AVAC and Avenir Health. “It is clear that we must continue to expedite development of an effective HIV vaccine alongside the critical efforts to accelerate and sustain broad and equitable access to effective antiretroviral therapy and new approaches for pre-exposure prophylaxis.”
“Adding a vaccine to a comprehensive HIV/AIDS response will hasten the end of the global epidemic and ensure that it won’t rebound,” said AVAC Executive Director Mitchell Warren. “A safe, effective and affordable AIDS vaccine is an essential complement to the existing treatment and prevention options, and this study highlights why accelerated investments are needed for both implementation of what we have and the development of what we still need.”
For more information on this please go to: https://www.iavi.org/press-releases/2016/570-modeling-shows-a-vaccine-is-essential-to-conclusively-ending-hiv-aids